Please note, "Covid deaths" include heart attacks, cancer, car accidents, murder, suicide, longterm illness, disease, infection, choking, drowning, flu, old age and anything else if the person was tested positive using the flawed PCR tests as admitted by all parties, at the time of death. Just to be absolutely clear, even if the deceased was not tested positive at the time of death but they tested positive a month before it is a covid death.
This is very openly admitted by all governments.
Common sense dictates that in order to stop misinformation, fear and scaring the public based on false data and propaganda this thread will now be locked and spreading misinformation like this may make one guilty in the eyes of Allah سبحانه وتعالى when so much information has been shared to fight this very real agenda.
Please refer to the doctors in the videos posted in this thread to understand and learn from hundreds of frontline doctors.
Unfortunately, readers still require "official" sources. So once again, here is just one "respected" News broadcaster
Sky News wrote:
Explaining the "strange anomaly", Sky News' Rowland Manthorpe said: "Essentially, there is no way to recover, statistically. So, if I tested positive for COVID-19 today and then I got hit by a bus tomorrow, then COVID-19 would be listed as my cause of death."
A government source confirmed that PHE's current method of calculation means if a person was previously diagnosed with COVID-19 but subsequently died of unrelated causes, their death would still be counted as part of PHE's daily coronavirus death tally.
Moderna says its Covid-19 vaccine is less effective against one coronavirus variant By ANDREW JOSEPH
JANUARY 25, 2021
Moderna is studying adding booster doses to its vaccine regimen after finding its Covid-19 vaccine was less effective against a coronavirus variant that was first identified in South Africa, the company said Monday.
In lab research that involved testing whether blood from people who had received the vaccine could still fend off different coronavirus variants, scientists found that there was a six-fold reduction in the vaccine’s neutralizing power against the variant, called B.1.351, than against earlier forms of the coronavirus, Moderna reported
There was no loss in neutralization levels against a different variant, called B.1.1.7, that was first identified in the United Kingdom. Both variants are thought to be more transmissible than other forms of the SARS-CoV-2 virus.
Moderna said that despite the reduction in neutralizing antibodies against B.1.351, the antibody levels generated by its vaccine “remain above levels that are expected to be protective.” Still, it said it was going to start testing whether adding a booster dose to its existing two-dose regimen could increase the levels of neutralizing antibodies even further, and that it was going to start investigating a booster specifically designed against B.1.351.
“These lower titers [of antibodies against B.1.351] may suggest a potential risk of earlier waning of immunity to the new B.1.351 strains,” Moderna said.
The announcement from Moderna gets at a nuance that scientists have been trying to stress as fears around vaccines and variants grew. Both the Moderna vaccine and the immunization from Pfizer-BioNTech produce such powerful levels of immune protection — generating higher levels of antibodies on average than people who recover from a Covid-19 infection have — that they should be able to withstand some drop in their potency without really losing their ability to guard people from getting sick.
“There is a very slight, modest diminution in the efficacy of a vaccine against it, but there’s enough cushion with the vaccines that we have that we still consider them to be effective,” Anthony Fauci, the top U.S. infectious diseases official, said Monday on “The Today Show.”
The coronavirus has been evolving throughout the pandemic, and scientists had expected that eventually, the virus would change so much that vaccines would need to be upgraded to better match dominant variants. But the appearance in recent months of the variants, which picked up mutations at much higher rates than the coronavirus was adding at the beginning of the pandemic, has moved up the date at which that might need to occur.
Experts say they need to now figure out how much less effective the vaccines can get before upgrades are needed, and what the regulatory process for approving such tweaks would look like.
Pfizer and BioNTech scientists have already reported their vaccine holds up against B.1.1.7, though they have not reported data yet against B.1.351. But researchers have been more concerned about B.1.351 because it contains a different set of mutations that, at least in lab experiments, had already helped the virus evade some of the immune protection generated in people who had an initial Covid-19 case.
Some of those same mutations of concern also appear in a different variant first seen in Brazil, called P.1.
In the meantime, if mutations do arise that deliver a blow to the vaccines’ strength, experts still say people should get them. Having some immune memory to the virus (which vaccines provide, almost like a substitute for an initial infection) is better than being completely vulnerable. You might still be able to get infected, and maybe even get sick, but giving your immune system even a small edge can reduce the chances you’ll get seriously ill.
Germany pushes back on AstraZeneca vaccine efficacy reports
Health ministry suggests media muddled statistics in concluding efficacy rates were as low as 8% in older people
The health ministry expects the European medicines regulator to publish its evaluation on Friday
January 26, 2021
Germany’s health ministry said it cannot confirm local media reports that the vaccine developed by AstraZeneca and Oxford university is less effective in people over 65 years old and suggested the newspapers had muddled statistics.
“At first glance it seems that the [newspaper] reports have mixed up two things: about 8 per cent of those tested in the AstraZeneca efficacy study were between 56 and 69 [years old], only 3-4 per cent over 70 (MHRA Approval Public Assessment Report),” the ministry said in a statement released on Tuesday. “But one cannot deduce an efficacy of only 8 per cent with older people from that.”
It added: “Moreover, the [European Medicines Agency] is currently evaluating the studies. It has been known since the autumn that in the first studies that AstraZeneca submitted fewer older people took part than in the studies of other producers.”
Macron: AstraZeneca vaccine 'quasi-ineffective' for over-65s
French President Emmanuel Macron said on Friday that AstraZeneca's coronavirus vaccine appeared not to be effective for people over 65 years of age.
Speaking to reporters only hours before the European Medicines Agency (EMA) recommended the vaccine for adults of all ages, Macron also questioned Britain's decision to delay the second dose of Covid vaccines to inoculate more people.
Macron said there was "very little information" available for the vaccine developed by the British-Swedish company and Oxford University.
"Today we think that it is quasi-ineffective for people over 65," he told the reporters, his office confirmed to AFP.
"What I can tell you officially today is that the early results we have are not encouraging for 60 to 65-year-old people concerning AstraZeneca," he said.
Nadhim Zahawi said the UK is storing a "library" of coronavirus mutations
There are currently about 4,000 variants of coronavirus around the world, the UK’s vaccines tsar has warned.
Nadhim Zahawi told Sky News there was a “library” of coronavirus mutations being stored to ensure the UK was ready to respond with updated vaccines.
“All manufacturers – Pfizer/BioNTech, Moderna, Oxford/AstraZeneca and others – are looking at how they can improve their vaccine to make sure we are ready for any variant,” said Mr Zahawai.
“There are about 4,000 variants around the world of Covid now.
“We have the largest genome sequencing industry – we have about 50 per cent of the world’s genome sequencing industry – and we are keeping a library of all the variants so that we are ready to be able to respond, whether in the autumn or beyond, to any challenge the virus may present, and produce the next vaccine so we can always protect the United Kingdom and of course the rest of the world as well.”
Single dose of Pfizer-Biontech vaccine may not protect elderly from Covid-19 infection
Researchers suggested that rapid antibody tests should be used to identify older people who have responded less well to the initial jab
Rhys Blakely, Science Correspondent
Tuesday February 02 2021, The Times
A significant proportion of people over 80 may have only a “poor” immune response after a single dose of the Pfizer-Biontech vaccine, researchers have said.
Three weeks later, one jab did not always produce the level of antibodies thought to be necessary to block infection. A second dose did lift them above this threshold, however.
Professor Ravi Gupta of Cambridge University, who led the study, said that there was also anecdotal evidence that jarred with assurances from government advisers about the level of protection offered by one dose. He knew of two cases where people who had been vaccinated had later been admitted to hospital.
“Certainly here in Cambridge we are seeing people who have been vaccinated coming into hospital with Covid-19 confirmed,” he said.
Vaccine strategy needs rethink after resistant variants emerge, say scientists
Oxford vaccine shown to have only limited effect against South African variant of coronavirus
Sun 7 Feb 2021
Leading vaccine scientists are calling for a rethink of the goals of vaccination programmes, saying that herd immunity through vaccination is unlikely to be possible because of the emergence of variants like that in South Africa.
The comments came as the University of Oxford and AstraZeneca acknowledged that their vaccine will not protect people against mild to moderate Covid illness caused by the South African variant. The Oxford vaccine is the mainstay of the UK’s immunisation programme and vitally important around the world because of its low cost and ease of use.
This cannot be undone and I am sure it will be greatly appreciated.
We apologise but you have been denied access to report posts in this thread. This could be due to excessively reporting posts and not understanding our forum rules. For assistance or information, please use the forum help thread to request more information. Jazakallah